rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.

@article{Ge2011rILYd4AH,
  title={rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.},
  author={Xiaowen Ge and Lin Wei Wu and Weiguo Hu and Stacey Fernandes and Chun Wang and Xin Li and Jennifer Rose Brown and Xuebin Qin},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 21},
  pages={6702-11}
}
PURPOSE Ofatumumab is an anti-CD20 antibody recently approved for treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL); it mediates much stronger complement-dependent cytotoxicity (CDC) than rituximab. Human CD59, a key membrane complement regulator that inhibits CDC, is highly expressed in B-cell malignancies and its upregulation is an important determinant of the sensitivity of B-cell malignancies to rituximab treatment. Previously, we have shown that the… CONTINUE READING
13 Citations
45 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Final analysis from the international trial of single-agent ofatumumab in patients with fludar- abine-refractory chronic lymphocytic leukemia

  • WG Wierda, TJ Kipps, J Mayer, T. Robak
  • Blood (ASH Annual Meeting Abstracts)
  • 2010
2 Excerpts

Ofatumumab mono- therapy for treatment of patients with relapsed/progressive diffuse largeB-cell lymphoma: results fromamulticenter phase II study

  • B Coiffier, A Bosly, KL Wu, G Verhoef, VE. Koen
  • Blood (ASH Annual Meeting Abstracts)
  • 2010
3 Excerpts

Similar Papers

Loading similar papers…